Modification of protein with BGL06, a novel branched oligoglycerol derivative

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 4, 2008, Pages 680-686

  Hiroyuki, Yamaguchi ^a   Toshiyuki, Suzawa ^a   Takaaki, Araki ^b   Masaki, Kamiya ^b   Hisao, Nemoto ^b   Motoo, Yamasaki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b Institute of Health Biosciences   (Japan)

Author keywords

Chemical modification; Conjugate; G CSF; Glycerol; Oligomer; PEG

Indexed keywords

GLYCEROL DERIVATIVE; MACROGOL; REAGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AQUEOUS SOLUTION; ARTICLE; CELL PROLIFERATION; LIPOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; THERMOSTABILITY;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCERIDES; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEAT; HUMANS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUCCINIMIDES;

EID: 40949084370     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.12.005     Document Type: Article

References (39)

1. Abuchowski A., and Davis F.F. Preparation and properties of polyethylene glycol-trypsin adducts. Biochim. Biophys. Acta 578 (1979) 41-46
2. Monkarsh S.P., Ma Y., Aglione A., Bailon P., Ciolek D., DeBarbieri B., Graves M.C., Hollfelder K., Michel H., Palleroni A., Porter J.E., Ussoman R.E., Roy S., and Pan Y.E. Positional isomers of monopegylated interferon α-2a isolation, characterization, and biological activity. Anal. Biochem. 247 (1997) 434-440
3. Esposito P., Barbero L., Caccia P., Caliceti P., D'Antonio M., Piquet G., and Veronese F.M. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Deliv. Rev. 55 (2003) 1279-1291
4. Suzawa T., Nagamura S., Saito H., Ohta S., Hanai N., Kanazawa J., Okabe M., and Yamasaki M. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. J. Control. Release 79 (2002) 229-242
5. Suzawa T., Nagamura S., Saito S., Ohta S., Hanai N., and Yamasaki M. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate. J. Control. Release 69 (2000) 27-41
6. Suzuki T., Kanbara N., Tomono T., Hayashi N., and Shinohara I. Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Biochim. Biophys. Acta 788 (1984) 248-255
7. Chapman A.P., Antoniw P., Spitali M., West S., Stephenes S., and King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17 (1999) 780-783
8. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjugate Chem. 6 (1995) 150-165
9. Greenwald R.B., Choe Y.H., McGuire J., and Conover C.D. Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55 (2003) 217-250
10. Kochendoerfer G.G., Chen S., Mao F., Sressman S., Traviglia S., Shao H., Hunter C.L., Low D.W., Cagle E.N., Carnevali M., Gueriguian V., Keogh P.J., Porter H., Stratton S.M., Wiedeke M.C., Wilken J., Tang J., Levy J.J., Miranda L.P., Crnogorac M.M., Kalbag S., Bottei P., Schindler-Horvat J., Savatski L., Adamson J.W., Kung A., Kent S.B.H., and Bradburne J.A. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 299 (2003) 884-887
11. Tsunoda S., Ishikawa T., Yamamoto Y., Kamada H., Koizumi K., Matsui J., Tsutsumi Y., Hirano T., and Mayumi T. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-α: a novel polymer-conjugation technique with a reversible amino-protective reagent. J. Pharmacol. Exp. Ther. 290 (1999) 368-372
12. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6 (1991) 181-202
13. Putnam D., and Kopecek J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122 (1995) 55-123
14. Gibauda S., Rousseaub C., Weingartena C., Favierc R., Douayc L., Andreuxb J.P., and Couvreura P. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J. Control. Release 52 (1998) 131-139
15. Jultani A., Li C., Ozen M., Yadav M., Yu D., Wallace S., and Pathak S. Paclitaxel and water-soluble poly (l-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res. 17 (1997) 4269-4274
16. Zunino F., Giuliani F., Savi G., Dasdia T., and Gambetta R. Anti-tumor activity of daunorubicin linked to poly-l-aspartic acid. Int. J. Cancer 30 (1982) 465-470
17. Uchio T., Baudys M., Liu F., Song S.C., and Kim S.W. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv. Drug Deliv. Rev. 35 (1999) 289-306
18. Maruyama K., Okuizumi S., Ishida O., Yamauchi H., Kikuchi H., and Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Pharm. 111 (1994) 103-107
19. Yamasaki M., Okabe M., Suzawa T., and Yokoo Y. New PEG2 type polyethylene glycol derivatives for protein modification. Biotechnol. Tech. 12 (1998) 751-754
20. Nemoto H., Cai J., Asao N., Iwamoto S., and Yamamoto Y. Synthesis and biological properties of water-soluble p-boronophenylalanine derivatives. Relationship between water solubility, cytotoxicity, and cellular uptake. J. Med. Chem. 38 (1995) 1673-1678
21. Nemoto H., Wilson J.G., Nakamura H., and Yamamoto Y. Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy. J. Org. Chem. 57 (1992) 435
22. Nemoto H., Wilson J.G., Nakamura H., and Yamamoto Y. Polyols of a cascade type as a water-solubilizing element of carborane derivatives for boron neutron capture therapy. J. Org. Chem. 60 (1995) 1478
23. Nemoto H., Kikuishi J., Yanagida S., Kawano T., Yamada M., Harashima H., Kiwada H., and Shibuya M. Design and synthesis of cholestane derivatives bearing a cascade-type polyol and the effect of their property on a complement system in rat serum. Bioorg. Med. Chem. Lett. 9 (1999) 205-208
24. Nemoto H., Araki T., Kamiya M., Kawamura T., and Hino T. A quantitative investigation of the water-solubilizing properties of branched oligoglycerols. Eur. J. Org. Chem. 18 (2007) 3003-3011
25. Yamasaki M., Asano M., Okabe M., Morimoto M., and Yokoo Y. Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND28 with polyethylene glycol. J. Biochem. 115 (1994) 814-819
26. Bowen S., Tare N., Inoue T., Yamasaki M., Okabe M., Horii I., and Eliason J.F. Relationship between molecular mass and duration of activity of polyethylene glycol conjugate granulocyte colony-stimulating factor mutein. Exp. Hematol. 27 (1999) 425-432
27. Uchida K., Yamaguchi K., and Yamasaki M. Primary and disulfide bond structures of a recombinant human granulocyte colony-stimulating factor derivative (ND28). J. Sep. Detection Sci. 18 (1997) 31-37
28. Holmes K.L., Palaszynski E., Fredrickson T.N., Morse H.C., and Ihle J.N. Correlation of cell-surface phenotype with the establishment of interleukin 3-dependent cell lines from wild-mouse murine leukemia virus-induced neoplasms. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 6687-6691
29. Okabe M., Asano M., Kuga T., Komatsu Y., Yamasaki M., Yokoo Y., Itoh S., Morimoto M., and Oka T. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood 75 (1990) 1788-1793
30. Asano M., Gomi K., and Okabe M. A colorimetric microassay for the biological activity of human granulocyte colony stimulating factor using murine myeloblastic leukemia, NFS-60 cells. Jpn. Pharmacol. Ther. 19 (1991) 2767-2773
31. Gross H., and Bilk L. Zur reaktion von N-hydroxysuccinimide mit dicyclohexylcarbodiimid. Tetrahedron 24 (1968) 6935-6939
32. Yamasaki M., Suzawa T., Kobayashi K., Konishi N., Akinaga S., and Maruyama K. Chemically modified polypeptides. United States Patent (Jun 24 2003) 583,267 B2
33. Gaertner H.F., and Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chem. 7 (1996) 38-44
34. Kuga T., Komatsu Y., Yamasaki M., Sekine S., Miyaji H., Nishi T., Sato M., Yokoo Y., Asano M., Okabe M., Morimoto M., and Itoh S. Mutagenesis of human granulocyte colony stimulating factor. Biochem. Biophys. Res. Commun. 159 (1989) 103-111
35. Arakawa T., Prestrelskia S.J., Kenneya W.C., and Carpenterb J.F. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Deliv. Rev. 46 (2001) 307-326
36. ICH Steering Committee, ICH harmonised tripartite guideline, step 4 of the ICH process, quality of biotechnological products: stability testing of biotechnological/biological products, 30 November 1995.
37. Niven R.W., Whitcomb K., Shaner L., Ralph L.D., Habberfield A.D., and Wilson J.V. Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF). J. Control. Release 32 (1994) 177-189
38. Auwera P., Platzer E., Xu Z.X., Schulz R., Feugeas O., Capdeville R., and Edwards D.J. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am. J. Hematology 66 (2001) 245-251
39. Szilvassy S.J., Meyerrose T.E., and Grimes B. Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells. Blood 95 (2000) 2829-2837